

ACHIEVING THE LATEST TREATMENTS FOR HEMOPHILIA

Madasheva Anajan Gazkhanovna*; **Abdiev Kattabek Makhmatovich****;
Ruziboeva Oyjamol Narzullaevna***

*Teacher,

Department of Hematology,
Samarkand State Medical Institute,
Samarkand, UZBEKISTAN

**Associate Professor,

Department of Hematology,
Samarkand State Medical Institute,
Samarkand, UZBEKISTAN

***Teacher,

Department of Hematology,
Samarkand State Medical Institute,
Samarkand, UZBEKISTAN

Email id: ozoda.madasheva@mail.ru

DOI: 10.5958/2249-7137.2022.00153.7

ABSTRACT

These article analysis innovative methods of the treatment of haemophilia A and B is the replacement therapy by preparations obtained from plasma of donors, or by recombinant DNA technology. Among the major shortcomings of unmodified drugs VIII and IX factors should be allocated between the low time circulation of the drug in the body of the patient and the delivery of antibodies (inhibitors) to a protein preparation that significantly reduces their effectiveness. The improvement of the efficiency and safety of recombinant preparations is achieved by removing B-domain of factor VIII molecule, pegylation or development of preparations of fusion proteins (fusion molecules of the preparation to the albumin or Fc-fragment of IgG).

KEYWORDS: *Hemophilia; Recombinant Factor VIII; Recombinant Factor IX; Pegylated Proteins; Monoclonal Antibody Preparations; Preparations Based Fusion Proteins; Aptamer; Antisense Oligonucleotides.*

REFERENCES:

1. Mannucci PM. AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J. Thromb. Haemost. 2003;1(10):2065–9.
 2. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia. 2006;12(6):102–6.
 3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–35.
-

4. Chalmers EA, Brown SA, Keeling D. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. *Haemophilia*. 2007;13(2):149–55.
5. Agostini D, Rosset C, Botton MR, Kappel DB, Vieira IA, Gorziza RP, Salzano FM, Bandinelli E. Immune system polymorphisms and factor VIII inhibitor formation in Brazilian haemophilia A severe patients. *Haemophilia*. 2012 Nov;18(6):e416-8.
6. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. *Haemophilia*. 2013;19(1):e1–47.
7. Madasheva AG, Makhmudova AD. Biochemical parameters in patients with hemophilia with muscle pathologies before and after treatment. *Young Scientists Forum*, 2021;(4):233-238.
8. Madasheva AG, Zhuraeva MZ. Biochemical indicators and complex treatment of patients with psoriasis with therapeutic plasmapheresis. *Achievements of science and education*, 2019;10(51):78-82.